Summit shows EHRs’ potential on drug regulation, marketing

The PharmEHR Summit in Philadelphia brought together physicians, EHR vendors, pharmaceutical executives, and the FDA to discuss the impact of EHRs on drug regulatory and marketing issues. Findings from a survey by PDR Network showed that over 30% of doctors had already adopted an EHR and a third planned to do so in the next 24 months. The survey also revealed that over 70% of doctors would find it valuable if their EHR included drug-related information or services. The FDA considers EHRs a medical device but doesn’t yet regulate them like drugs or other devices.